Clinical Trial Update: A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study comparing Sabirnetug IV and Sabirnetug with rHuPH20 SC in healthy participants to assess safety, tolerability, and pharmacokinetics. The trial has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Sabirnetug (sabirnetug)
• rHuPH20 (recombinant human hyaluronidase PH20)

Snippet

Sponsor: Acumen Pharmaceuticals | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED